A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema
1 other identifier
observational
172
1 country
1
Brief Summary
Diabetic retinopathy(DR) is a sight threatening condition that occurs in persons with diabetes. DR arises as a consequence of damage to the retinal blood vessels and is related to the high and fluctuating sugar levels in the blood stream. An eye with DR will have abnormal appearing retinal blood vessels which become engorged and dilated, leaky and fragile or undergo closure. The net result is a picture of haemorrhage and or ischaemia (lack of blood supply). A particular feature of DR is the accumulation of fluid in the macula which is the central part of the retina and responsible for detailed eye sight. This peculiar form of DR is called Diabetic Macular Oedema (DMO). DMO can occur in isolation without other features of DR. DMO is commoner in type 2 diabetes where insulin resistance and abnormalities of blood fats are found. The investigators wish to study DR and DMO using high resolution retinal imaging and functional tests in normal participants, those participants with diabetes without any overt signs of disease and those with DR and DMO in order to understand how the condition develops and whether there are any unique risk factors that can be identified
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2014
CompletedFirst Submitted
Initial submission to the registry
April 28, 2016
CompletedFirst Posted
Study publicly available on registry
August 23, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2017
CompletedApril 4, 2019
April 1, 2019
2.2 years
April 28, 2016
April 2, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Presence of DMO evaluated from the optical coherence tomography (OCT) images
The outcome measures will be assessed at the end of 3 months
Study Arms (2)
Cases
Persons with type 1 or type 2 DM with features of DR and or DMO ranging from extremely mild to severe.
Control definition
Persons with a history of type 1 or type 2 DM without any clinical features of DR or DMO in either eye or persons without a history of DM and without retinal disease in either eye.
Eligibility Criteria
Potential participants with DR of different severity levels ranging from minimal DR to severe DR with or without DMO who attend the diabetic clinics will be invited to participate. Opportunistic sampling will be used to ensure that the different severity levels of DR and or DMO will be adequately represented.The Northern Ireland Cohort Longitudinal Study On ageing (NICOLA), a non-interventional epidemiological study of healthy ageing in older adults aged 50 years and above has commenced and is currently recruiting some 8500 participants. Participants in NICOLA who are known to have DM or have been recently diagnosed with DM will be approached and asked if willing to return for detailed functional testing of the eye. This will supplement the group with DM but with no changes of DR. Control participants with DM but without DR will be recruited from the metabolic clinics of the Belfast Trust.
You may qualify if:
- Group 1 (Healthy controls without DM):
- Persons older than 18 years without DM
- Fundus free of any signs of retinal disease
- Best Corrected Visual Acuity of 20/40 (73 ETDRS letters) in both eyes
- Group 2 (Persons with DM with no retinopathy):
- Persons with Type 1 or type 2 diabetes older than 18 years
- Normal fundus, Absence of features of DR or DMO in both eyes
- Best Corrected Visual Acuity 20/40 (73 ETDRS letters) in at least one eye
- Group 3:
- Persons with Type 1 or type 2 diabetes 18 years and older
- Fundus signs of mild, moderate or severe DR and or DMO
- Best Corrected Visual Acuity 20/200 (33 ETDRS letters) or better
You may not qualify if:
- Recent ocular surgical procedures performed within the previous 3 months
- Presence of ocular confounding disorders such as neovascular age related macular degeneration, glaucoma or active uveitis
- Serious life threatening conditions that would preclude attendance in the longitudinal part of the study
- Neurological conditions that can impair vision
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
NI clinical Research Facility,51 Lisburn Road
Belfast, BT9 7AB, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Prof Usha Chakravarthy, Phd FRCopth
Queens University Belfast
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 28, 2016
First Posted
August 23, 2016
Study Start
November 1, 2014
Primary Completion
January 1, 2017
Study Completion
January 1, 2017
Last Updated
April 4, 2019
Record last verified: 2019-04